ArticleAnesthesiology2016
A Novel Strategy to Reverse General Anesthesia by Scavenging with the Acyclic Cucurbit[n]uril-type Molecular Container Calabadion 2.
Article in Anesthesiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 46 citations in OpenAlex.
- A tetrachloroanthracene-walled glycoluril trimer: solvent-dependent conformational switching and host-guest binding.Organic & biomolecular chemistry · 2026Article
- Acyclic cucurbituril as sequestrant for acetaminophen.Chemical communications (Cambridge, England) · 2026Article
- Current and Developing Approaches for Facilitating Emergence from General Anesthesia.Anesthesiology · 2025Review
- Developing novel drugs to reverse neuromuscular block: do we need them?British journal of anaesthesia · 2025Article
- Acyclic cucurbit[Beilstein journal of organic chemistry · 2025Article
- Insoluble methylene-bridged glycoluril dimers as sequestrants for dyes.Beilstein journal of organic chemistry · 2025Article
- Supramolecular nanotherapeutics based on cucurbiturils.Journal of nanobiotechnology · 2024Review
- Insoluble Acyclic Cucurbit[n]uril-Type Receptors Capture Iodine from the Vapor Phase.Chemistry (Weinheim an der Bergstrasse, Germany) · 2024Article
- Nanotherapeutics for Alleviating Anesthesia-Associated Complications.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Review
- Evaluation of polyanionic cyclodextrins as high affinity binding scaffolds for fentanyl.Scientific reports · 2023Article
- Anthracene-Walled Acyclic CB[n] Receptors: in vitro and in vivo Binding Properties toward Drugs of Abuse.ChemMedChem · 2022Article
- In Vitro and In Vivo Sequestration of Methamphetamine by a Sulfated Acyclic CB[n]-Type Receptor.Chemistry (Weinheim an der Bergstrasse, Germany) · 2021Article
- In Vitro and In Vivo Sequestration of Phencyclidine by MeChemistry (Weinheim an der Bergstrasse, Germany) · 2021Article
- Acyclic Cucurbituril Featuring Pendant Cyclodextrins.Supramolecular chemistry · 2021Article
- Supramolecular hosts as in vivo sequestration agents for pharmaceuticals and toxins.Chemical Society reviews · 2020Review
- Calabadion 1 selectively reverses respiratory and central nervous system effects of fentanyl in a rat model.British journal of anaesthesia · 2020Article
- The Molecular-Container Calabadion-2 Prevents Methamphetamine-Induced Reinstatement in Rats: A Potential Approach to Relapse Prevention?The international journal of neuropsychopharmacology · 2020Article
- Triptycene Walled Glycoluril Trimer: Synthesis and Recognition Properties.New journal of chemistry = Nouveau journal de chimie · 2020Article
- Acyclic Cucurbit[n]uril-Type Containers as Receptors for Neuromuscular Blocking Agents: Structure-Binding Affinity Relationships.Croatica chemica acta. Arhiv za kemiju · 2019Article
- Triazole functionalized acyclic cucurbit[n]uril-type receptors: host·guest recognition properties.Organic & biomolecular chemistry · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundCalabadion 2 is a new drug-encapsulating agent. In this study, the authors aim to assess its utility as an agent to reverse general anesthesia with etomidate and ketamine and facilitate recovery.
methodsTo evaluate the effect of calabadion 2 on anesthesia recovery, the authors studied the response of rats to calabadion 2 after continuous and bolus intravenous etomidate or ketamine and bolus intramuscular ketamine administration. The authors measured electroencephalographic predictors of depth of anesthesia (burst suppression ratio and total electroencephalographic power), functional mobility impairment, blood pressure, and toxicity.
resultsCalabadion 2 dose-dependently reverses the effects of ketamine and etomidate on electroencephalographic predictors of depth of anesthesia, as well as drug-induced hypotension, and shortens the time to recovery of righting reflex and functional mobility. Calabadion 2 displayed low cytotoxicity in MTS-3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium-based cell viability and adenylate kinase release cell necrosis assays, did not inhibit the human ether-à-go-go-related channel, and was not mutagenic (Ames test). On the basis of maximum tolerable dose and acceleration of righting reflex recovery, the authors calculated the therapeutic index of calabadion 2 in recovery as 16:1 (95% CI, 10 to 26:1) for the reversal of ketamine and 3:1 (95% CI, 2 to 5:1) for the reversal of etomidate.
conclusionsCalabadion 2 reverses etomidate and ketamine anesthesia in rats by chemical encapsulation at nontoxic concentrations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.